Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.
about
Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitationsA review of the efficacy and safety of mirodenafil in the management of erectile dysfunctionThe role of phosphodiesterase-5 inhibitors in prostatic inflammation: a reviewThe new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitorsEvidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasiaComparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysisLower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment.Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review.A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunctionSignalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options.Recent advances in management of bladder overactivity.Benign prostatic hyperplasia: from bench to clinicEjaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography.The role of combination medical therapy in benign prostatic hyperplasia.New insights into the pharmacology of the bladderAre phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?Prospective pharmacologic therapies for the overactive bladderNovel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.Drugs and future candidates.Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV studyTestosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis.Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.Developmental and spinal cord injury-induced changes in nitric oxide-mediated inhibition in rat urinary bladder.Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.itAlpha1-adrenoceptor subtypes and lower urinary tract symptomsLower urinary-tract symptoms and testosterone in elderly menPDE5 inhibitors beyond erectile dysfunction.PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunctionEpinephrine is associated with both erectile dysfunction and lower urinary tract symptomsLower urinary tract symptoms and sexual dysfunction: a common approach.Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.Activation of the nitric oxide-cGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G.Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link.
P2860
Q24649617-A58D7155-12D0-47BF-B876-20D39320BCD2Q26749094-94F4CC4C-3449-477B-9FB4-85CBFE219CCCQ26785428-ED89C4ED-76FB-4EF0-947A-C881D25BBFC4Q27025700-CEAFDBE9-D9A2-4726-9ED7-6D56AC9DB619Q28077954-9AE4A255-3AAF-4225-84A6-180D127BBBE9Q28542960-BC0B6D68-A161-4C0F-81B3-5B4D6163FB7CQ33289952-ECC24E7B-8D4F-4778-98A7-26B7CD3F781CQ33706631-380FAEF7-A4AB-4B85-BFF7-60A1048A809FQ33744285-D1D2715A-1EAF-493F-B424-71BA40C2C809Q34112983-6A9DF94A-81C7-47CB-A768-5B13C0801987Q34114694-88CD3946-AF4A-4418-AAEF-D3F64EA72AC9Q34167658-6AF4BAD9-EB76-4ACD-9CCA-C321826FD41AQ34216723-0AF8FA48-84C2-4E99-96C0-32087AAC67DCQ34595957-F42CB3AA-0446-4349-8FA5-C3177C75D0A1Q34877827-BF32F499-D509-40A7-81C6-4F280A1635B2Q34931019-2C8B4EC6-6C31-44BD-8252-FD246601C3DDQ35050805-9F304C2C-ECE6-44F2-8E04-7E854558C8DCQ35076367-7A47B02B-B869-46B5-B9DD-EFE8D9BC9958Q35089850-92513984-C85E-4912-B893-EB23A21CCB9AQ35183603-DD0085E4-90D3-4F05-B4CB-06AD63A85880Q35347721-0EF8ABE9-15F2-4277-A98F-1AD1C67E63C5Q35603121-01C32AEC-5DE5-452C-A2A8-99B912391859Q35924409-452897C5-A0DA-43CC-96ED-CADF15DD5232Q35993920-DAC3752D-F8DE-442E-8436-BF642B5D6BCEQ36006813-5EDF1D44-0A03-4E10-83EA-FCB80777111DQ36056990-2CD02D69-7434-4753-9044-1FAE56ACAB9AQ36319042-66133798-8D99-4789-9A98-7E804BF359A9Q36379355-63CEC957-6694-44DC-BBA3-330A8941B8A4Q36579735-F8766EF7-A79F-4544-A373-209CB7080FEAQ36839032-F2F75349-5C03-495F-9546-F9FFC076D60EQ36878017-BE7133E4-BD1B-4C37-9193-2AED47504290Q37025381-21EF0C81-0332-41AB-9740-54ABC43822F6Q37030511-A0C4D823-A21F-4786-8934-DC904A4BDAAEQ37038183-3D1EF3E5-EA76-4C63-B542-65434E4E0722Q37040760-EF63B0FE-64BB-4EDB-88AF-C7AD21E22820Q37092203-FE53D06E-14F9-42F8-801E-A5DEF1D677ABQ37097048-368A68C7-5280-408E-9F1B-751A8AC38272Q37148383-C0145D20-0F33-4E1E-B219-46B8EAC76B0DQ37298493-CFFC28E1-8863-4497-ABB6-CAF6FA36A153Q37323310-DFDF7C1A-0454-43E4-A3E9-C17314E8B265
P2860
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Sildenafil citrate improves er ...... andomized, double-blind trial.
@ast
Sildenafil citrate improves er ...... andomized, double-blind trial.
@en
Sildenafil citrate improves er ...... andomized, double-blind trial.
@nl
type
label
Sildenafil citrate improves er ...... andomized, double-blind trial.
@ast
Sildenafil citrate improves er ...... andomized, double-blind trial.
@en
Sildenafil citrate improves er ...... andomized, double-blind trial.
@nl
prefLabel
Sildenafil citrate improves er ...... andomized, double-blind trial.
@ast
Sildenafil citrate improves er ...... andomized, double-blind trial.
@en
Sildenafil citrate improves er ...... andomized, double-blind trial.
@nl
P2093
P1476
Sildenafil citrate improves er ...... andomized, double-blind trial.
@en
P2093
Gene van den Ende
Jay M Young
Joseph L Camps
Kevin T McVary
Li-Jung Tseng
William Monnig
P304
P356
10.1016/J.JURO.2006.10.055
P407
P577
2007-03-01T00:00:00Z